Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prosed EC
- Development stage
- Unknown
- Lead developer
- Star Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Prosed EC is a multi-ingredient oral medication used to alleviate symptoms of lower urinary tract irritation, such as pain, burning, and spasms. It is a combination of six active components: methenamine (anti-infective), methylene blue (mild antiseptic), phenyl salicylate (analgesic), benzoic acid (antiseptic), and the anticholinergics atropine and hyoscyamine. Developed by Star Pharmaceuticals, the drug features an enteric coating to reduce gastric irritation. It works by relaxing smooth muscle in the urinary tract via muscarinic receptor antagonism and providing local anti-infective action through the conversion of methenamine to formaldehyde in acidic urine.
- Brand names
- Prosed EC
02
Targets
COXmAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on Prosed EC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prosed EC.